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Abstract 
 
Chronic cardiac iron overload directly correlates with cardiac dysfunction and 
may ultimately cause heart failure. Although recent studies have suggested that altered 
calcium homeostasis and increased reactive oxygen species (ROS) play roles in iron 
overload-induced cardiac dysfunction, the exact mechanism(s) of oxidative stress-
mediated cardiac inflammation, matrix remodelling and cell death remain unclear. Here 
we examined iron-induced cardiac damage in terms of oxidative stress, inflammation and 
apoptosis in an in vitro model of cardiac iron overload using the H9c2 cardiac cells. We 
also investigated the effect of secoisolariciresinol diglucoside (SDG), a component of 
flaxseed, on the above mentioned parameters. H9c2 cells were treated with 50 μM iron 
and a pre-treatment of 500 μM SDG was performed by dissolving SDG into serum- and 
antibiotic-free Dulbecco's Modified Eagle's Medium and for each treatment type, cells 
were incubated for 24 hours. Cardiac iron overload resulted in increased intracellular 
ROS while SDG treatment prevented this increase, as measured by the H2DCFDA assay 
using flow cytometry. Increased gene expression of inflammatory mediators Tumor 
Necrosis Factor (TNF)-α, interleukin (IL)-10 and interferon (IFN)γ, as well as matrix 
metalloproteinases (MMP)-2 and 9, and antioxidants glutathione reductase (GSR), 
superoxide dismutase (SOD)-2 and peroxiredoxin (Prdx)-6 and a decrease in SOD 
concentration correlated with increased apoptosis as measured by active caspase 3/7 
activity and increase in FOXO3. SDG attenuated the increase of gene expression of 
inflammatory and apoptosis mediators as well as the increase of caspase 3/7 activity 
caused by iron treatment. SDG also lead to an increase in gene expression of antioxidants 
GSR, SOD-2 and Prdx-6 when compared to iron treatment. Cardiac iron overload also 
resulted in an increase in protein levels of p70S6K1 and a decrease in the AMPK levels. 
The increase of p70S6 and decrease in AMPK levels was prevented by SDG. Pre-
treatment with SDG attenuated the iron-induced increases in oxidative stress, 
inflammation and apoptosis, suggesting a cardio-protective role for SDG against cardiac 
iron overload.  
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Lay Summary 
 
The Lakehead University Department of Biology’s lists its mission statement as: 
“Faculty and students in the Department of Biology are bound together by a common 
interest in explaining the diversity of life, the fit between form and function, and the 
distribution and abundance of organisms.”  This research project, centered in the realm of 
the human sciences, aims to understand the mechanisms behind cardiac iron overload in 
an in vitro model and how secoisolariciresinol diglucoside, a component found in flax 
seed, can act as a natural therapeutic agent capable of protecting cardiac cells during iron 
overload. 
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Introduction 
 
Iron is a transition metal that is essential to almost all eukaryotic cells for cell 
metabolism and function. Iron is a component of hemoglobin, myoglobin, mitochondrial 
electron transport chain enzymes, the cytochrome p450 system and many other proteins 
[1; 2]. The biological importance and toxicity of iron is largely attributable to its ability to 
undergo oxidation reduction reactions between its ferric Fe3+ and ferrous Fe2+ states [1; 
3]. However, an over abundance of iron can result in such complications as 
cardiomyopathy, cirrhosis, and diabetes [1; 3; 4; 5]. Primary iron overload, or 
hemochromatosis, is a common autosomal recessive disorder whereby mutation of the 
hemochromatosis associated gene causes impaired feedback inhibition of iron uptake, 
resulting in maximal absorption [1; 3; 5]. Secondary iron overload typically derives from 
dietary or transfusional excesses, iron-loading anemias, and chronic liver diseases [2; 4]. 
As the iron burden on the body increases it outpaces the ability of transferrin to bind to it 
resulting in increased amounts of labile plasma iron [5] and its deposition in various 
tissues, including the heart [3].  
 
Iron absorption and transport-Transferrin bound iron 
The human body uses about 20 mg of iron per day for hemoglobin synthesis, the 
production of approximately 200 billion erythrocytes and an additional 4-5 mg for the 
production of cellular proteins including mitochondrial proteins and muscle myoglobin 
[1; 2; 6]. Total iron content in normal individuals is relatively fixed, with men (50 mg 
Fe/kg) having slightly higher iron levels than women (40 mg/kg) [1]. Dietary iron exists 
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in two main forms: heme iron, ferrous iron from hemoglobin and myoglobin in animal 
tissue, and non-heme iron, ferric oxides and salts, ferritin, and lactoferrin [7; 8] Most of 
the iron in the body is contained in hemoglobin but it can also be stored in hepatocytes 
and macrophages as ferritin [1; 7]. Iron equilibrium requires carefully controlled and 
efficient absorption by duodenal enterocytes, release into plasma, transport in plasma by 
transferrin, storage, release from storage, uptake by erythroblasts for synthesis of heme 
and recycling from senescent erythrocytes [7]. Iron is delivered to most cells of the body 
via the blood as ferric iron bound to serum protein transferrin. Transferrin-bound iron is 
relatively nonreactive. Movement of iron within the body involves a combination of 
transporters, including transferrin receptors (TfR1 and TfR2), dimetal transporter 1 
(DMT1), ferroportin and a heme receptor [1]. Iron transport requires redox cycling 
between the ferric (Fe3+) to the ferrous (Fe2+) states, which can be done by several ferric 
reductases including duodenal-cytochrome b and ferroxidases, such as ceruloplasmin and 
hephaestin [1; 6; 9]. The most prevalent method for iron transport involves the binding of 
plasma transferrin-bound iron to TfR1 or TfR2. TfR1 is expressed in all cells while TfR2 
is only expressed in hepatocytes, duodenum and erythroid precursors [1; 6]. Transferrin 
and TfR1/2 complexes are internalized into acidic endosomes where the iron is reduced 
to Fe2+ and released into the cytosol by the DMT1. Iron also enters cells by DMT1 
transporters, which are H+/divalent metal symporters capable of transporting many other 
divalent metals. DMT1 and transferrin iron transport systems are regulated in a negative-
feedback manner by iron responsive elements [1; 10]. Ferroportin is a divalent iron 
export protein that is expressed on the surface of enterocytes, macrophages, hepatocytes 
and placental cells [1; 9]. Ferroportin exports reduced iron into the plasma, whereupon 
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the iron is oxidized and binds to transferrin [1; 6]. Finally, iron can also be imported as a 
heme–iron complex into selected tissues such as intestinal enterocytes and reticulo-
endothelial macrophages by a heme receptor. Once internalized heme-bound iron is 
released by heme oxygenase [1]. About 1 mg of iron is lost daily in the stool from 
sloughed iron-containing duodenal enterocytes and from sloughed skin cells [7; 11]. An 
average additional 1 mg of iron is lost daily from menstruation in women and bleeding 
from other causes will further increase iron loss [7]. 
 
Iron absorption and transport-Non-transferrin bound iron 
Although cellular iron uptake is tightly regulated elevated body iron does occur 
under several disease conditions due to excessive intestinal iron absorption or repeated 
blood transfusions. This leads to surplus iron accumulation in tissues such as liver, 
pancreas and heart. When transferrin becomes iron-saturated excess free iron resides as 
non-transferrin bound iron (NTBI) in the blood stream, which is then transported into 
selected tissues [1]. The actual mechanism of NTBI transport into cells currently remains 
unclear, particularly since it is clear that certain tissues are more susceptible to NTBI than 
others. Cardiomyocytes, neurons, beta cells of the pancreas and pituitary cells seem to be 
popular targets of NTBI. Reduction of Fe3+ to Fe2+ by a membrane-associated ferri-
reductase system is required for NTBI uptake into excitable cells [1; 10]. At first it was 
suggested that DMT1 was responsible for NTBI uptake into excitable cells but DMT1 
protein expression decreases when iron is elevated in cardiomyocytes and DMT1 is 
expressed at extremely low levels in most excitable tissue including the heart [1; 12; 13]. 
Recently it has been suggested that divalent metal transporters L-type Ca2+ channels 
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(LTCC) are responsible for the transport of NTBI into cells. Excitable cells and tissues 
with the greatest risk in iron overload have high duty cycles for LTCC activity [1], 
supporting the idea that these channels are responsible for cellular uptake of NTBI. 
 
Primary iron overload 
 Primary iron overload, commonly referred to hemochromatosis, is the most 
common hereditary genetic disorder affecting Canadians [14]. There are four distinctive 
subtypes with Type 1, or classical hemochromatosis, being the most common [1; 2; 9]. It 
is caused by an autosomal recessive disorder mutation of the hemochromatosis associated 
(HFE) gene. A Cys282Tyr mutation on the major intracellular histocampatibility-like 
protein responsible for heterodimeric protein formation in the endoplasmic reticulum has 
been identified as a main cause of hemochromatosis. The HFE gene is involved with iron 
absorption of the gastro intestine and facilitates the binding of transferrin, iron's carrier 
protein in the blood. The Cys282Tyr mutation results in the gene’s inability to provide 
feedback inhibition of iron uptake in the gut wall. The intestines perpetually interpret a 
strong transferrin signal as if the body were deficient in iron. This leads to maximal iron 
absorption from ingested foods [1; 3]. Type 1 hemochromatosis can also be caused by a 
substitution of aspartate for histidine at position 63 (H63D) of the HFE gene. The 
Cys282Tyr mutation is primarily limited to individuals of northern European ancestry 
with an allele frequency of about 10%, while the H63D mutation occurs at allele 
frequencies greater than 5% in Mediterranean/ Middle East regions and the Indian 
subcontinent [1; 3; 15]. Type 2 hemochromatosis, or juvenile hemochromatosis, is also 
an autosomal recessive inherited disorder. It results in a large amount of iron burdens and 
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organ damage at a young age, mostly under the age of 30. The disorder is caused by 
mutations in an iron-regulatory protein hemojuvelin (HJV gene). Type 3 is also an 
autosomal recessive condition caused by a mutation in the transferrin receptor TfR2, 
which normally allows iron to enter a cell. The final type, Type 4, is the only type of 
primary hemochromatosis that is inherited as an autosomal dominant condition. It is 
linked to mutations and altered function of the iron exporter ferroportin (specifically the 
SLC40A1 gene), the second most common cause of hemochromatosis after mutations in 
HFE [1; 3; 9]. The excess iron is deposited in the cytoplasm of parenchymal cells of 
various organs and tissues, including the liver, pancreas and heart [16]. Long-standing 
hemochromatosis can lead to increased complications of heart failure, liver cancer, and 
cirrhosis. Also, heterozygous individuals have an increased risk for myocardial infarction 
and cerebrovascular disease [4].  
 
Secondary iron overload 
 Secondary iron overload is caused by an underlying disease or condition, usually 
a blood disorder, which results in increased free iron. In patients with secondary iron 
overload total serum iron levels range from 20 to 60 μM, while normal range is 8-15 μM 
[1; 6]. It occurs in patients with disorders of erythropoiesis, the process by which red 
blood cells are produced, which cause hereditary anemias including α-thalassemia, β-
thalassemia and sickle cell anemia [1; 16]. In these patients iron overload occurs because 
of repeated blood transfusions coupled with increased gastrointestinal iron absorption, 
leading to conditions similar to those seen in primary iron overload. With blood 
transfusions iron burden can increase very rapidly through the combined impact of 
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increased iron absorption and transfusion derived iron (in hemoglobin). Therefore these 
patients may present with the consequences of iron toxicity to the liver, heart, and 
pancreas many years earlier than do patients with primary iron overload [16]. α- and β-
thalassemias are caused by mutations resulting in defective synthesis of the α- and β-
globin chains of hemoglobin, respectively, and are the most common monogenetic 
diseases in humans [1]. Individuals with β-thalassemia are characterized by profound 
anemia, so regular blood transfusions are necessary [16]. Sickle cell anemia is the most 
common and severe form of sickle cell disease, caused by the homozygous presence of 
sickle haemoglobin due to a glutamate to valine mutation in the beta-globulin gene (Hgb 
S) [1; 3]. Patients with sickle cell disease, like individuals with β-thalassemia, require 
chronic transfusions [4]. Several other clinical disorders are associated with secondary 
iron overload including sideroblastic anemia, myelodysplastic syndrome, acute myeloid 
leukemia, congenital dyserythropoietic anemia and chronic renal failure. Sideroblastic 
anemia is characterized by mitochondrial iron overload in erythroblast and is associated 
with systemic iron overload, suggesting an important role for mitochondria in cellular 
iron metabolism [1; 17]. In patients with chronic renal failure and end-stage kidney 
disease, anemia is common due in part to erythropoietin deficiency that often necessitates 
therapy with intravenous iron [1; 4].To prevent iron accumulation caused by blood 
transfusions the use of intensive chelation therapy is required, starting at the time that 
there is a commitment to long-term transfusion [16]. 
 
Cardiac iron overload 
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 Iron overload cardiomyopathy is a common cause of cardiovascular deaths 
worldwide in the second and third decades of life [3; 1]. The amount of myocardial iron 
accumulation predicted to occur over 20 years, a relevant period for patients with iron 
overload, is estimated to be about 10 mg of iron per gram of myocardial tissue [1; 18]. In 
patients with hemochromatosis or thalassemia major cardiovascular disease contributes 
significantly to their mortality and morbidity [1; 19]. It has been shown to lead to 
restrictive cardiomyopathy with prominent early diastolic dysfunction that invariably 
progresses to end-stage dilated cardiomyopathy characterized by impaired systolic 
function and reduced mean arterial blood pressure often accompanied by arrhythmias 
including atrioventricular block, conduction defects, bradyarrhythmias, tachyarrhythmias 
and sudden cardiac death [1; 3; 19; 20]. Iron overload may also facilitate myocardial 
ischemia-reperfusion injury because of an increased formation of ROS and reduce 
antioxidant reserve [1; 3]. Iron accumulation occurs initially in the ventricular followed 
by the atrial myocardium. During the progression of iron overload, iron accumulates in 
the ventricular wall, the epicardium, the papillary muscles, and the ventricular septum. 
First degree heart block and supraventricular arrhythmias are correlated with the extent of 
iron deposition in the atrial myocardium [2; 22]. Although the precise mechanism 
underlying cardiomyocyte dysfunction induced by iron overload is not entirely clear [1] 
recent studies suggest that generation of free radicals play an important role. 
 
Transport of iron in the heart 
 Recent studies suggest that LTCCs are responsible for the transport of NTBI into 
the cardiac cells. LTCCs are primarily utilized for the transport of Ca2+ but they are able 
to transport many other divalent cations. LTCCs are the only Fe2+ transporter whose 
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activity increases with elevated iron, consistent with NTBI uptake in the heart under iron 
overload conditions [1; 23]. The link between LTCCs and iron uptake in excitable tissues 
is consistent with the observation that iron uptake is approximately tenfold higher in 
cardiomyocytes, that have a large amount of LTCCs, than in fibroblasts, that have few 
LTCCs [1; 24; 25]. Studies with mice using LTCC blockers amlodipine and verapamil 
reduced intracellular myocardial iron accumulation and reduced oxidative stress while 
protecting diastolic and systolic cardiac function. Then, cardiac-specific LTCC 
overexpression caused increases in myocardial iron accumulation and oxidative damage 
in proportion to the elevated Ca2+ currents that were, again, reduced with LTCC blockers 
[1; 10], further supporting the theory of transport of NTBI by LTCCs. Finally, 
involvement of LTCC in iron transport is also supported by the protective actions of 
taurine supplementation against myocardial iron accumulation, oxidative damage, and 
altered cardiac structure and function [1; 20]. NTBI entering cardiomyocytes is 
effectively trapped in the cytosol, following rapid redox cycling [1].  
 
Diagnosis 
 The diagnosis of iron overload is based on physical examination with routine 
screening and monitoring of iron levels. Screening is necessary for the diagnosis of iron 
overload, and monitoring after the diagnosis has been made is required to manage therapy 
effectively and prevent iron toxicity. Several biochemical and genetic studies, screening 
and monitoring tests and direct biopsy are used to assess patients for the presence of iron 
overload cardiomyopathy [3; 7]. Genetic screening is used to diagnose primary iron 
overload; genetic screening for the C252Y and H52D mutations for type 1 primary 
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hemochromatosis is now widely available as well as hemoglobin electrophoresis for the 
detection of congenital hemoglobinopathies [3]. There are two main tests for serum iron 
measurement currently used; serum ferritin and serum transferrin saturation. Serum 
ferritin is non-invasive and inexpensive; making it the most convenient laboratory test 
used to determine iron overload.  A serum ferritin level greater than 200 µg/L in 
premenopausal women and a serum ferritin level greater than 300 µg/L in men and 
postmenopausal women is a marker of excess iron [3; 7; 9]. Problems can arise in the 
accuracy of this test because ferritin is an acute-phase reactant, and serum levels increase 
in chronic inflammation and infection. Also, serum ferritin levels decrease in vitamin C 
deficiency [7; 26]. Serum transferrin saturation measures the proportion of transferrin 
bound to iron and is derived by dividing serum iron by total iron-binding capacity. An 
indicator of primary iron overload is serum transferrin saturation greater than 45%. This 
test is only effective in diagnosing secondary iron overload when used in combination 
with serum ferritin [3; 7]. Imaging studies are used to visualize tissue iron. The 
widespread use of cardiac magnetic resonance imaging (MRI) measurement has lead to 
an increased detection of myocardial iron overload [3]. MRI measures tissue iron 
concentration indirectly by detecting the paramagnetic influences of storage iron on the 
proton resonance behavior of tissue water [7; 27]. MRI is suitable for ongoing assessment 
of iron levels in the heart and for estimation of total body iron, as well as for serial 
evaluation of therapy for iron toxicity [7]. Endomyocardial biopsy is not routinely used 
but can serve as definitive assessment of tissue iron stores while allowing a detailed 
histological assessment of end-organ damage. However, the distribution of stored iron in 
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the heart is not homogeneous so the test may not provide a true estimate of iron content. 
It is also highly invasive and can cause serious complications [7; 3; 28]. 
 
Treatment 
 Currently there are two types of treatment available for patients with iron 
overload; phlebotomy and chelation therapy. Phlebotomy, the removal of blood from the 
body, begun early can be expected to result in normal lifespan. Phlebotomy should be 
continued after primary iron depletion to prevent reaccumulation of iron, with a goal to 
keep the serum ferritin concentration at 50 ng/mL or less. Usually, patients with primary 
iron overload are often diagnosed and treated only after iron overload becomes advanced, 
after damage has occurred. Oxidative stress may persist or rebound during the chronic 
maintenance phase of phlebotomy therapy in patients with primary iron overload, 
suggesting that close attention to iron control is necessary [3]. For transfusional iron 
overload in patients with underlying anemia, phlebotomy is not a feasible form of 
treatment [7; 16]. Chelation has been shown to improved ventricular function, prevents 
ventricular arrhythmias and reduces mortality in patients with secondary iron overload 
[3]. Three iron chelating agents are currently available: subcutaneous iron chelator 
deferoxamine mesylate (desferrioxamine, DFO, Desferal®) and oral chelators deferasirox 
(Exjade®) and deferiprone (Ferriprox®) [3; 7]. The primary routes of excretion for all 
chelators are the urine and stool [7]. Deferoxamine is a hexadentate iron chelator, 
forming a complex (ferrioxamine) with iron at a 1:1 molar ratio with a stability constant 
of 1031, but has a very short plasma half-life of 5-10 minutes [7; 16]. A daily dose of 
500–1000 mg (20–40 mg/kg/day) can be given over a period of 8–24 h through 
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subcutaneous infusion via a portable pump [7]. In two thirds of patients with thalassemia 
major conventional chelation treatment with deferoxamine does not prevent excess 
cardiac iron deposition, placing them at risk of heart failure and its complications [3]. 
Deferoxamine is effective and has few major side effects but it has the disadvantages of 
high cost and difficulties in patient compliance with the subcutaneous infusion regimen 
[16]. Deferasirox has a longer half-life than deferoxamine at 8-16 hours, making it 
suitable for once-daily oral administration with 24 hour chelation. It is just as effective as 
deferoxamine in transfusion-dependent patients but has side effects including 
gastrointestinal disturbances and rash [7]. Deferiprone has a plasma half-life of 47-134 
minutes and therefore must be administered three times daily orally. It is more effective 
than deferoxamine in the removal of myocardial iron and, in comparison to deferoxamine 
alone, combination treatment with deferiprone reduced myocardial iron and improved 
heart and endothelial function in thalassemia major patients with cardiac iron overload [7; 
3]. Major side effects include agranulocytosis, musculoskeletal and joint pain, gastric 
intolerance, and zinc deficiency. The risk of agranulocytosis requires a weekly complete 
blood count, and serum alanine transaminase should be measured monthly for 3 to 6 
months and then every 6 months [7]. Although chelation therapy has been consistently 
shown to reduce the cardiovascular burden from secondary iron overload, chelation 
therapy is cumbersome and associated with the toxic side effects described above, 
thereby setting a limit its impact on possible clinical outcome [3]. 
 
Reactive oxygen species 
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 Redox reactions are the transfer of electrons from an electron donor to an electron 
acceptor [29]. Free radicals are formed when a molecule contains one or more unpaired 
electron(s) in the outermost orbital, making the molecule a highly reactive species [30; 
31]. Due to its unique diradical configuration oxygen is a major source of free radicals 
[30]. Reactive oxygen species (ROS) include free radicals superoxide (O2˚-) and hydroxyl 
(˚OH), as well as the reactive molecule hydrogen peroxide (H2O2) [32]. ROS are 
generated intracellularly by two metabolic sources: the mitochondrial electron-transport 
chain and oxygen-metabolizing enzymatic reactions, where the mitochondrial electron-
transport chain is the major source of ROS in the heart [29; 32]. Mitochondria provide 
energy in the form of adenosine triphosphate (ATP) to the cell through oxidative 
phosphorylation, the process by which ATP is formed. Electrons are transferred from 
NADH or FADH2 generated through the Krebs cycle flow along the respiratory transport 
chain through a series of electron transport carriers located on the inner mitochondrial 
membrane called complexes I, II, III and IV. Normally, only 1% to 2% of electrons leak 
out to form O2˚-, and this is scavenged by manganese superoxide dismutase (SOD2). 
However, under pathophysiologic conditions, the electron transport chain may become 
uncoupled, leading to increased O2˚- production [32]. ROS are important for several 
biological functions; they are required for oxidative burst reaction, which is essential to 
phagocytes [33], and act as signaling molecules that regulate numerous cellular processes 
[29]. ROS’s role as signaling molecules can also be detrimental in instances of high 
levels of ROS and can cause significant damage to cellular proteins, membranes and to 
nucleic acid, leading to single strand breaks and chromosomal alterations [32]. ROS 
signaling can also lead to high levels of inflammation and even cell death. In iron 
13   
 
overload condition free iron can catalyze the production of hydroxyl radicals through the 
Fenton reaction (Figure 1). The resulting ˚OH are much more reactive than either O2˚- 
 
Figure 1 The Fenton Reaction. Image and text from Shawky, M. et al. Oxidative Stress and 
Cardiac Failure (2003) [4]. Iron interacts with cellular oxidizing and reducing ROS hydrogen 
peroxide (H2O2) and superoxide radical (O2−˚) produced from the electron transport chain during 
ischemia and reperfusion. Iron is able to accept and donate electrons readily by interconverting 
between Fe3+ and Fe2+, which makes it a useful component of cytochromes, hemoglobin, and 
enzymes. However, ROS can be converted to hydroxyl radicals (OH˚) by interacting with Fe2+ 
through the Fenton Reaction. OH˚ is highly reactive and it itself can damage many organic 
molecules. 
or H2O2, causing an increase in damage to structural membranes, enzymes, mitochondria, 
DNA, and ultimately apoptosis [4]. Numerous studies have shown that ROS activation is 
increased in the cardiovascular system in response to various stressors and in failing heart 
[33]. ROS has been shown to be involved in the development of pressure overload 
hypertrophy [32; 34]. There is also evidence that increased levels of ROS observed 
following Myocardial infarction (MI) are directly involved in the development of 
contractile dysfunction and plays a multi-factoral role in myocardial remodelling [32; 35] 
ROS also play a significant role in tissue necrosis and reperfusion injury [33; 36]. 
Together, these observations strongly suggest a role for ROS in cardiovascular 
pathophysiology. 
 
Inflammation 
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Inflammation, like oxidative stress, can result in both beneficial effects or be 
detrimental and is implicated in several cardiac disease conditions. Specifically, 
inflammatory response is an integral component of the host response to tissue injury or 
host invasion but plays a particularly active role after myocardial infarction [37]. The 
inflammatory response is mediated by a variety of signaling molecules, particularly 
inflammatory cytokines. Cytokines are a group of relatively small molecular weight 
proteins (15–30 kDa) secreted by cells in response to stress. They form a complex 
network of signals regulating the growth, differentiation, and functions of almost all types 
of cells, but they are more implicated in the host’s immune response to infections and 
other forms of stresses. Cytokines are classified as pro-inflammatory and anti-
inflammatory [38]. Pro-inflammatory cytokines such as tumor necrosis factor-alpha 
(TNF-α), a major contributor to cardiac inflammation, are elaborated soon after MI injury 
and can acutely regulate myocyte survival/apoptosis and trigger additional cellular 
inflammatory response [37]. Recent studies suggest that cytokines not only induce ROS 
production but also are themselves induced by ROS in what can be called the ‘vicious 
cycle’ (Figure 2) of redox-cytokine interaction [37; 39; 40]. In studies on isolated adult 
rat cardiomyocytes exposed to TNF-α, researchers have shown an increase in ROS and in 
events leading to oxidative stress [38; 41]. ROS can act as a messenger molecule, 
initiating pathways and transcription factors, which can lead to an increase of cytokines 
cascade [37]. Thus, this ‘vicious cycle’ that indicates perpetual increases in inflammation 
and oxidative stress appears to have significant effects on the development and 
progression of cardiovascular disease and ultimately heart failure. 
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Figure 2 The vicious cycle between oxidative stress and inflammation. There is evidence of a 
‘vicious cycle’ between oxidative stress and inflammation. In redox imbalance there is cardiac 
stress which can lead to an increase in free radicals and a decrease in antioxidant, then leading to 
oxidative stress. Oxidative stress increases inflammation and TNF-α level. An increase in 
inflammation causes the release of more inflammatory cytokines. Inflammatory cytokines, 
particularly TNF-α, can cause an increase in the level of ROS, continuing the cycle of oxidative 
stress and inflammation, leading to cellular stress and damage.  
 
Tumor necrosis factor-alpha   
TNF-α is a key cytokine that has been shown to play important physiological and 
pathological roles in the heart. It can stimulate antigen presentation, adhesion molecule 
expression on endothelial cells, inflammatory cell activity and expression of matrix-
degrading enzymes [38; 42; 43; 44]. It belongs to a family of structurally related 
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cytokines, the TNF superfamily, which includes more than 20 different ligands. TNF-α 
initiates activation of intercellular pathways by binding to TNF receptors, which are 
found on a variety of cell types [38]. There are two types of TNF-α receptors isolated so 
far [38; 43; 44; 45; 46]. TNFR1 seems to be ubiquitous while TNFR2 seems to be more 
restricted to cells of hematopoietic origin [38; 47]. Binding of TNF-α to TNFR1 will 
induce binding of TNFR-associated death domain (TRADD) to the inner membrane 
portion of TNFR1. TRADD will then recruits and binds to molecules Fas-associated 
death domain protein (FADD), receptor-interacting protein (RIP) and TNFR-associated 
factor 2 (TRAF2). TRAF2 and RIP stimulate pathways leading to activation of 
transcription factor nuclear factor-kappaB (NF-κB) and of jun N-terminal kinases/ 
activating protein-1 (JNK/AP-1), whereas FADD mediates activation of apoptosis by 
binding to a death effector domain (DED) [42; 48]. NF-κB can cause the expression of 
more inflammatory cytokines, including TNF-α, while JNK/AP-1 can lead to the release 
of ROS from the mitochondria [42]. The source of TNF-α in the heart is not fully 
understood. Activation of the immune system after myocardial injury may be responsible 
for the release of cytokines in the injured myocardium, failing heart may be the source of 
TNF-α production, in which elevated serum levels of TNF-α represent spillover of 
cytokines that were produced within the myocardium, leading to the secondary activation 
of the immune system, or decreased cardiac output in heart failure may lead to the 
elaboration of TNF-α due to an under-perfusion of systemic tissue that allows 
translocation of endotoxins, which activates cytokine production [38; 49; 50].  
 
Interleukin 10  
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Anti-inflammatory cytokines also play a role in the inflammatory response in the 
heart. Interleukin-10 (IL-10), demonstrates potent anti-inflammatory properties through 
inhibiting the production of various pro-inflammatory cytokines including TNF-α [51; 
52]. The biological activities of IL-10 are dependent on two receptors that bind IL-10 
with high affinity, IL-10R1, and low affinity, IL-10R2 [38]. The IL-10/IL-10R interaction 
activates the tyrosine kinase Jak1 and Tyk2, which activates the cytoplasmically localized 
inactive signal transducer and activator of transcription (STAT) protein 1,3 and 5, and 
results in the translocation and gene activation [38; 53; 54]. IL-10 appears to be a 
neutralizing component of inflammation and serves to reduce both duration and 
magnitude of the process. Studies with IL-10 gene deficient mice showed an 
overproduction of inflammatory cytokines and the development of chronic inflammation 
disease [38; 54; 56]. It acts as an anti-inflammatory cytokine by inhibiting the synthesis 
of a number of cytokines such as interferon gamma (IFNγ), IL-2, and TNF-α. As 
mentioned earlier, TNF- α is transcriptionally controlled by NF-κB and it was suggested 
that IL-10 may exert a significant part of its anti-inflammatory properties by inhibiting 
this transcription factor [38]. There is also evidence that IL-10 can act as an antioxidant 
by inhibiting the release of ROS [38; 57; 58]. Recently, studies have shown that 
improvement in cardiac function after dexamethasone, growth hormone, or steroid 
treatment has been associated with an increase in IL-10 content. Also, studies in rats have 
shown a significant decrease in IL-10 content after 4, 8, and 16 weeks of MI [38; 51; 59; 
60; 61]. Recent evidence has shown an importance in the ratio between TNF-α and IL-10. 
Studies on isolated cardiomyocytes have shown that exposure to IL-10/ TNF-α in the 
ratio of 1 was found to be consistent with normal healthy myocytes. At an IL-10/ TNF-α 
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ratio of 1, IL-10 treatment was able to antagonize the deleterious effects of TNF-α with 
respect to generation of ROS, antioxidant enzymes, and lipid peroxidation [38; 51; 62]. In 
MI-induced rats, where the cardiac function was also depressed, there is a significant 
decrease in the IL-10/ TNF-α ratio [38; 51]. A higher IL-10/ TNF-α does not provide any 
additional protection, emphasizing an optimal ratio of 1 for IL-10/ TNF-α [38]. 
 
Interferon gamma 
IFNγ is an important pro-inflammatory cytokine in immune reactions, however its 
role occurs to be much larger. Besides its immunologic activity [63; 64] IFNγ is involved 
in atherogenesis, inflammation and apoptosis [63; 65; 66; 67; 68]. It acts through its 
specific receptor composed of two subunits: IFNγ R1 (ligand binding) and R2 (signal 
transduction). IFNγ binds to cell surface receptors and activates members of the JAK 
kinase family. Activated JAK kinases phosphorylate the STAT family of transcription 
factors. STAT proteins homo-or heterodimerize and form complexes with other 
transcription factors to activate transcription of IFN-stimulated genes (ISGs) [69; 70; 71]. 
It is through the activation of ISGs that IFNγ is capable of inducing a wide range of 
cellular processes including inflammation and apoptosis. ISGs can act as a transcription 
factor, resulting in increased inflammation, or induce death inducing ligands, resulting in 
apoptosis [69].  
 
Matrix metalloproteinase 
 Matrix metalloproteinases (MMPs) are synthesized in inflammation and 
participate in tissue remodeling and the destructive effects of cardiovascular diseases 
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associated with enhanced oxidative stress [72]. MMPs are generally secreted in an 
inactive form but can be readily activated within minutes of ischemia by ROS, cytokines 
and hypoxia. ROS and cytokines stimulate transcription factors NF-κB, Ets, and AP-1 to 
stimulate MMP expression. [37; 73; 74; 75]. MMP2 and MMP9 are the two major 
remodelling proteins in the heart and are known to play key roles in various cardiac 
disease states [76]. MMP2 and 9 specialize in the degradation of type IV collagen, the 
major structural component of basement membranes. A previous study demonstrated that 
H9c2 cardiomyoblasts exposed to oxidative stress exhibited increased MMP2 activity, 
leading to cleavage and activation of the apoptotic protein, glycogen synthase kinase-3β 
[72]. It has also been shown that MMP2 and MMP9 are robustly increased during various 
stages of congestive heart failure. Furthermore, studies have shown that MMP9 has a 
major role in ventricular remodelling associated with endothelial and myocyte apoptosis 
[77]. Hearts expressing highest levels of MMP-2 and MMP-9 proteins also have a high 
amount of collagen deposition and impaired diastolic function [37; 78]. 
 
Antioxidants  
An antioxidant is a molecule capable of inhibiting the oxidation of other 
molecules, removing free radical intermediates and inhibiting other oxidation reactions, 
thus they play a protective role against oxidative stress damage. They do this by being 
oxidized themselves, so antioxidants are often reducing agents. There are many studies 
showing that both enzymatic and non-enzymatic antioxidants offer protection in different 
pathophysiological conditions, where ROS are known to be involved [30]. There are a 
number of antioxidants that are naturally found in the heart, including glutathione 
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reductase (GSR), manganese superoxide dismutase (SOD2) and peroxiredoxin (Prdx)6. 
GSR is important for maintaining reduced glutathione (GSH) levels. GSH is a 
multifunctional tripeptide that directly or indirectly regulates a number of biological 
processes, such as DNA synthesis, ion transport, enzyme activity, transcription, signal 
transduction, and antioxidant defenses [30; 79; 80; 81; 82; 83]. It is used as a reducing 
agent for enzymes that detoxify lipid or oxygen radicals as well as a scavenger of radicals 
in the aqueous portion of the cell, thereby protecting protein thiol groups [30; 84]. As 
well as the reduced state, glutathione can exist as an oxidized state (GSSG). Studies have 
shown that GSH depletion and accumulation of its oxidized form, glutathione disulfide 
(GSSG), occur in the heart muscle within minutes of initiating oxidative stress [79; 85]. 
The change in GSH status elicited by oxidative stress is due to an increased cellular 
demand for GSH. In GSH the thiol group of cysteine is able to donate a reducing 
equivalent ROS and thus becomes reactive itself. It readily reacts with another reactive 
GSH to form GSSG. In order to act as an antioxidant GSSG must be converted back to 
GSH. GSR readily reduces GSSG to GSH in oxidative stress conditions, making it a good 
indicator of oxidative stress [30; 79; 81; 83; 86]. Superoxide dismutase (SOD) catalyzes 
the dismutation of O2˚- to H2O2 and O2. Previous studies have shown that SOD offers 
protection against ischemia-reperfusion injury [30; 87; 88; 89]. SOD2 is a nuclear-
encoded homotetrameric enzyme, mitochondria-localized that is the primary defense 
against mitochondrially generated ROS [29; 90]. Prdx6 is a member of a relatively new 
family of antioxidant enzymes that is involved in redox regulation [91]. Prdx6 is the only 
mammalian 1-Cys member of the peroxiredoxin superfamily that is expressed in all the 
vital organs, including the heart [91; 92]. Prdx6 antioxidant activity lies in its ability to 
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reduce H2O2 and hydroperoxides into water and alcohol, respectively [91; 93]. Studies 
have shown that mice with a targeted mutation of Prdx6 are susceptible to oxidative 
stress and mouse hearts devoid of Prdx6 were indeed susceptible to ischemia-reperfusion 
injury [91; 94]. 
 
Apoptosis 
 Apoptosis is a tightly regulated program of cell death. It is required for normal 
organ development, control of cell number and deletion of harmful, nonfuntional and 
abnormal cells. Apoptotic cells are characterized by cell shrinkage, plasma membrane 
blebbing, chromatin condensation and DNA fragmentation [95]. Increase in apoptosis 
plays a major role in the development of various cardiovascular disorders and heart 
failure [96; 97]. Iron overload has been linked to cardiomyocyte loss due to apoptosis and 
enhanced apoptosis in iron-overload cardiomyopathy could be linked to altered 
mitochondrial function [20; 98; 99]. Apoptosis is activated in cardiac myocytes by 
multiple stressors that are commonly seen in cardiovascular disease such as increased 
oxidative stress and cytokine production [97; 100; 101; 102]. Different stressors induce 
different pathways of apoptosis. ROS is believed to initiate the intrinsic pathway, which 
is apoptosis initiated by an intracellular stressor. The first step is the activation of pro-
apoptotic proteins in the cytoplasm, including B-cell lymphoma (Bcl)-2-associated X 
protein (Bax). Bax binds to and opens channels on the mitochondria surface allowing the 
release of cytochrome c. Anti-apoptotic proteins, such as Bcl-2, can prevent the release of 
cytochrome c by binding to and forming a heterodimer with Bax, preventing the opening 
of mitochondrial channels. In oxidative stress there is a decrease in ratio of Bcl-2/Bax, 
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which leads to the release of cytochrome c [96; 97]. Cytochrome c, once released into the 
cytosol, binds to apoptotic protease activating factor (Apaf)-1, leading to a 
conformational change. Cytochrome c/Apaf-1 then recruits and activates initiator caspase 
caspase-9, creating an apoptosome [97; 103; 104]. The apoptosome cleaves and activates 
effector caspases caspase-3 and -7. Activated effector caspases translocate to the nucleus, 
then cleave the DNA repairing enzyme, poly (ADP-ribose) polymerase (PARP) and 
activate endonucleases which cleave DNA, culminating in apoptotic cell death [96; 97; 
103; 105]. Apoptosis initiated by stressors from outside the cell is referred to as extrinsic 
apoptosis, such as TNF-α. It begins with the binding of TNF-α to previously mentioned 
death domains TNFR1 and/or Fas. TNFR1 will then bind and activate intracellular 
FADD, while Fas first binds to and activates TRADD, which in turn binds to FADD. 
Activated FADD binds to pro-caspase 8 leading to cleavage and activation of initiator 
casepase caspase-8. Caspase-8 has two roles: it can cleave and activate caspase-3, 
resulting in apoptosis, or initiate the release of cytochrome c by the mitochondria, causing 
intrinsic apoptosis [97; 106]. As mentioned earlier, ISGs are able to activate death 
domains, including Fas and TNFR1. This activation also leads to activation of caspase-8 
and ultimately apoptosis, suggesting a role for IFNγ in cell death [69]. Apoptosis is 
mediated by many transcription factors, including the forkhead box subfamily O (FOXO) 
family. Besides apoptosis, FOXOs mediate many aspects of physiology, including stress 
response and metabolism [107]. FOXOs are ubiquitous in most cell types, where FOXO3 
is commonly expressed in cardiomyocytes [108]. Some studies have shown that FOXO3 
can have beneficial effects on cardiomyocytes by preventing cardiac hypertrophy [108; 
107]. However, FOXO3 can also act as a pro-apoptotic transcription factor and has 
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shown to be a promoter of the Fas gene [109]. FOXO3’s mechanism of action depends 
on cell type and types of stressor, so its exact effects in cardiovascular disease and 
damage remains an active area of research.   
  
Autophagy 
 As stated, cardiac myocytes responses to various stressors, such as excess iron 
and/or oxidative stress, includes molecular modifications, inflammation and remodeling, 
thus ultimately leading to various cardiac disorders including hypertrophy, arrhythmias, 
MI and heart failure. Autophagy, a catabolic pathway for bulk turnover of long-lived 
proteins and organelles via lysosomal degradation, is a cellular response to these 
stressors. Autophagy is initiated by the formation of a single membrane structure, 
possibly derived from the sarcoplasmic/endoplasmic reticulum. Fusion of the tips of the 
isolation membrane results in the formation of a double-membrane structure known as 
the autophagosome, which surrounds portions of the cytoplasm and organelle. 
Autophagosomes undergo a series of maturation steps and finally fuse with the lysosome 
called the autophagolysosome, in which the sequestered contents and the inner 
membranes of autophagosomes are degraded by the lysosomal hydrolases [110; 111; 112; 
113]. Autophagy can promote cell survival by generating free amino acids and fatty acids 
required to maintain function during nutrient-limiting conditions, or by removing 
damaged organelles and intracellular pathogens [110; 114; 115; 116]. Autophagy might 
also promote cell death through excessive self-digestion and degradation of essential 
cellular constituents [110; 117; 118; 119]. In the heart, autophagy is upregulated in 
response to ischemia/reperfusion [97; 120; 121]. However, the functional significance of 
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increased autophagy in the heart is not clear; autophagy has been reported to protect 
against cell death as well be the cause of cell death [97; 121; 122; 123]. During ischemia, 
oxygen and nutrient supplies are decreased, causing activation of adenosine 
monophosphate-activated protein kinase (AMPK) and inactivation of mammalian target 
of rapamycin (mTOR), which in turn leads to autophagy for cell survival. Also, beclin 1, 
a promoter of autophagy, is negatively regulated by interaction with Bcl-2 [121; 124; 
125; 126]. In reperfusion AMPK is inactive while mTOR is activated, the opposite of 
what is seen in ischemia. Instead, expression of beclin 1 is markedly upregulated. Bcl-2 is 
degraded by the ubiquitin–proteasome system, which is activated during oxidative stress. 
The combination of upregulation of beclin 1 and downregulation of Bcl-2 during the 
reperfusion phase stimulates the activity of beclin 1, thereby stimulating autophagic cell 
death [121; 124; 126; 127]. Recent studies suggest that there is cross talk between 
autophagy and apoptosis. Autophagy protein (Atg)5, an essential autophagy protein, has 
been reported to activate apoptosis. It was found that over expression of Atg5 increased 
the cell’s susceptibility to apoptosis following stimulation with several death triggers. 
Death stimulation resulted in cleavage of Atg5, and truncated Atg5 induced cytochrome c 
release and apoptosis. Over expression of Bcl-2 protected against Atg5-mediated 
mitochondrial dysfunction. This suggests that Atg5 can serve as a molecular switch 
between autophagy and apoptosis [97; 128]. Another study reported that Atg5 associated 
with FADD to mediate IFNγ-induced cell death [97; 129].  
 
Cell survival 
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In condition distress, cells may promote cell survival pathways in order to 
compensate with the stressor, leading to increased cellular growth, proliferation and 
differentiation [130]. Enlargement of cardiomyocytes has been reported to result from an 
increase in protein content and activation of p70S6 Kinase 1 (p70S6K1). p70S6K1 plays 
a major role in regulating the phosphorylation of 40S ribosomal S6 protein and selective 
translation of a family of mRNAs that contain an oligopyrimidine tract at the 5’-
transcriptional start site [130; 131]. p70S6K1 is activated through the phosphoinositide 3-
kinase (PI3K) pathway. PI3K catalyzes addition of a phosphate group to the 3’ position 
of the sugar ring in a phosphoinositide. Its products act on multiple downstream effectors 
that interact with Src homology-2 and pleckstrin homology domains of serine/threonine 
and tyrosine kinases. It is these kinases that contribute to phosphorylation and activation 
of p70S6K1 [130]. Studies have shown treatment with H2O2 activates PI3K and thus 
p70S6K1 in cardiomyocytes. Activated p70S6K1 also lead to increased cardiomyocyte 
size, supporting the theory that activation of p70S6K1 plays an important role in 
cardiomyocyte hypertrophy [130]. Mammalian target of rapamycin (mTOR) can also be a 
regulator of p70S6K1 in stress conditions. Activation of mTOR is regulated by energy 
metabolism by adenosine monophosphate-activated protein kinase (AMPK). AMPK 
reserves cellular energy content and serves as a key regulator of cell survival or death in 
response to pathological stress. The precise role that AMPK plays in cardiac metabolism 
remain incompletely understood. AMPK may play a role in altering cardiac myocyte 
morphology and proliferation. The main AMPK activator, LKB1, is in fact a tumor 
suppressor gene. Activated AMPK inhibits mTOR signaling and cell growth and 
proliferation [132; 133; 134]. Recent evidence indicates that AMPK-mediated 
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modification of gene expression leads to cardiac protection from anoxia and ischemia 
[132; 135; 136]. Another study showed that in cardiac muscle cells resveratrol, an 
antioxidant found in red wine, induced activation of AMPK and inhibited the occurrence 
of cell death caused by treatment with H2O2 [137]. More research is required to better 
understand the role of cardiac AMPK in energy metabolism.  
 
Secoisolariciresinol diglucoside  
 Secoisolariciresinol diglucoside (SDG) is an antioxidant phytochemical present in 
flaxseed.  After ingestion, SDG is converted to secoisolariciresinol, which is further 
metabolised to the mammalian lignans enterodiol and enterolactone. A growing body of 
evidence suggests that SDG metabolites may provide health benefits due to their weak 
oestrogenic or anti-oestrogenic effects, antioxidant activity, ability to induce phase 2 
proteins and/or inhibit the activity of certain enzymes [138; 139; 140; 141; 142]. The 
chemical structure of SDG, as well as Secoisolariciresinol (SECO) and 
Nordihydroguaiaretic acid (NDGA) are shown in Figure 3. SDG has been shown 
 
Figure 3 Chemical structure of SDG Secoisolariciresinol diglucoside. Image and text from 
Prasad, K. Molecular and Cellular Biochemistry (2000). The chemical structure and molecular 
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weight of Secoisolariciresinol diglucoside (SDG) (A), Secoisolariciresinol (SECO) (B), and 
Nordihydroguaiaretic acid (NDGA) (C). Antioxidant activity of SDG could be due to the 
structural similarity of the aglycone SECO with known antioxidant NDGA. 
to decrease the production of inflammatory mediators and scavenge ROS to reduce 
oxidative stress. In vitro studies have shown that SDG and its metabolites, SECO, EL and 
ED, possess antioxidant activity and were effective in preventing lipid peroxidation of 
liver homogenate [143]. There have been multiple studies on the effect of SDG on 
cardiovascular health. SDG prevents the development of hypercholesterolemic 
atherosclerosis, induces angiogenesis-mediated cardioprotection and prevents the 
development of type 1 diabetes. SDG treatment reduced the development of 
hypercholesterolemic atherosclerosis by causing a decrease in serum cholesterol, LDL-C, 
and lipid peroxidation product and an increase in HDL-C and antioxidant reserve in 
rabbits fed a high cholesterol diet [144]. SDGs effect on arterial pressures in anesthetized 
rats was investigated. SDG in the doses of 3, 5, and 10 mg/kg produced dose-dependent 
reductions in systolic, diastolic, and mean arterial pressures [145]. The angiogenic 
properties of SDG were investigated in three different models. First, in an in vitro model, 
human coronary arteriolar endothelial cells treated with SDG showed a significant 
increase in tubular morphogenesis. Second, in an ex vivo ischemia/reperfusion model, 
SDG-treated showed an increased level of aortic flow and functional recovery. Also, 
SDG reduced infarct size compared and also decreased cardiomyocyte apoptosis. Third, 
in an in vivo myocardial infarction model, SDG increased capillary density and 
myocardial function as evidenced by increased fractional shortening and ejection fraction 
[146]. To study the effects SDG had on diabetes diabetic prone BioBreeding rats were 
used as a human type I diabetes model. SDG prevented the development of diabetes by 
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approximately 71%; pevention in development of diabetes by SDG was associated with a 
decrease in serum and pancreatic-MDA and an increase in antioxidant reserve [144]. 
Currently, there have been no studies to date investigating the role of SDG in abrogating 
oxidative stress-induced cardiac damage in an iron overload model.  
 
 
Figure 4 Iron overload induces inflammation, oxidative stress and cell death. Excess iron has 
been attributed to an increase in cellular inflammation, oxidative stress and death. Free iron 
causes the expression of inflammatory cytokines leading to inflammation. Iron can also cause the 
formation of  reactive oxygen species causing oxidative stress. Excess iron can cause cell death 
by leading to an increase in apoptosis. Reactive oxygen species and inflammatory cytokines can 
also contribute to apoptosis. The increase in inflammation, oxidative stress and cell death caused 
by iron overload is associated with cardiac dysfunction and may ultimately cause heart failure. 
As previously stated, the mechanism/s of iron induced cardiac damage, as well as 
SDG in an iron overload model are not fully understood. In this study we hypothesize 
increase oxidative stress and inflammation in cardiac iron overload will correlate with 
increased apoptosis (Figure 4), and pre-treatment with SDG may attenuate these effects. 
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To better understand the mechanism/s of cardiac damage in an iron overload model as 
well, as protection by SDG, multiple markers of oxidative stress, inflammation, 
remodelling, cell death and cell survival were investigated.      
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Methods 
 
H9c2 cardiac cell line 
Rat cardiac cells (H9c2) were obtained from the American Type Culture 
Collection (Manassas, VA) and grown in Dulbecco’s Modified Eagle’s Medium 
(DMEM) (Sigma-Aldrich, St. Louis, MO), fetal calf serum (Hyclone, Pittsburgh, PA) and 
penicillin-streptomycin (Invitrogen, Carlsbad, CA). All H9c2 cells were cultured at 37 
°C, 5 % CO2 and used for experimentation upon reaching approximately 95 % 
confluence. All experiments were completed with cultures between passage 34 and 57. 
 
Ammonium iron (III) citrate preparation 
 Different concentrations of iron (0.1, 1, 10, 50, 100, 200 and 300 μM) iron 
solution was prepared by dissolving ammonium iron (III) citrate (Sigma-Aldrich, St. 
Louis, MO) into serum- and antibiotic-free DMEM. Treatment cells were incubated for 
24 hours at 37˚C. 
 
Secoisolariciresinol diglucoside 
 Different concentrations of Secoisolariciresinol diglucoside (SDG) (10, 50, 
100, and 500 μM) was prepared by dissolving SDG into serum- and antibiotic-free 
DMEM. Treatment cells were incubated for 24 hours at 37˚C. SDG was provided by Dr 
Prasad at the University of Saskatchewan. 
  
Trypan Blue Exclusion assay 
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 The diazo dye, Trypan Blue ((3Z,3'Z)-3,3'-[(3,3'-dimethylbiphenyl-4,4'-
diyl)di(1Z)hydrazin-2-yl-1-ylidene]bis(5-amino-4-oxo-3,4-dihydronaphthalene-2,7-
disulfonic acid), is a stain used to discern living from dead cells. It is cell-impermeable 
and penetrates only damaged, non-viable cells with compromised membrane integrity. 
Viable cell counts were performed via automated Trypan Blue Exclusion assay using a 
Vi-Cell XR Cell Viability Analyzer (Beckman Coulter), wherein 0.5 mL of diluted, 
trypsinized cell suspensions were loaded, mixed with Trypan Blue reagent, and live/dead 
cell counts accessed via 50 individual sub-samples measured using the Vi-Cell XR Cell 
Viability Analyzer software. The total viable cell count was used when passaging or 
standardizing cell samples for experimentation. 
 
MTT assay 
 The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay is 
used as a quantitative index of activity of mitochondrial and cytosolic dehydrogenases, 
which, in living cells, reduce the yellow tetrazolium salt to produce a purple formazan 
dye that can be measured spectrophotometrically [261]. In the present studies the MTT 
assay was used to measure cell viability. Cells were seeded onto sterile flatbottom 96-
well plates (Corning) and incubated overnight to achieve the desired confluence. Plated 
cells were subjected to iron, SDG or SDG pre-treatment followed by iron treatments in 
serum- and antibiotic-free media. With t = 4 hours of treatment time remaining, MTT 
reagent (Thiazolyl Blue Tetrazolium Bromide; Sigma, St. Louis, MO, USA) was added to 
wells to achieve a final concentration of 10 % (v/v), and cells were incubated at 37 °C for 
an additional 4 hours, during which time the MTT reagent was converted to purple 
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formazan crystals in living cells according to their metabolic activity. Following this, the 
incubation media was aspirated and 50 μL of dimethylsulfoxide per well was added to 
solubilise the formazan crystals. Following 10 minutes of agitation on a Belly Dancer 
shaker (Stovall, Greensboro, NC, USA) at its highest setting, absorbance was measured 
spectrophotometrically at a wavelength of 490 nm (650 nm correction wavelength) using 
a PowerWave XS Microplate Spectrophotometer (BioTek, Winooski, VT, USA). 
Viability of treated wells was assessed relative to control wells, which were considered to 
represent 100 % viability.  
 
Reactive oxygen species indicator assay 
 CM-H2DCFDA (5 - (and -6) – chloromethyl - 2′, 7′ - dichlorodihydrofluorescein 
diacetate, acetyl ester) is used as a cell-permeable indicator of ROS. This molecule 
remains non-fluorescent until the acetate groups are removed by intracellular esterases as 
oxidation occurs within the cell. In addition, esterase cleavage of the lipophilic blocking 
groups yields a charged form of the dye that is much better retained by cells than the 
parent compound. Moreover, the chloromethyl derivative of H2DCFDA used here allows 
for covalent binding to intracellular components, permitting even longer retention within 
the cell. Cells were seeded onto sterile flat-bottom 25 cm2 culture flasks (Corning) and 
grown overnight to achieve the desired confluence. Cells were subjected to iron, SDG or 
SDG pre-treatment followed by iron treatments in serum- and antibiotic-free media. 
Following this the cells were washed with PBS and stained for 30 minutes with CM-
H2DCFDA (Molecular Probes, Eugene, OR, USA) under standard incubation conditions. 
Stained cells were washed with PBS and  detached from the flask using trypsin and 
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suspended in PBS for flow cytometric analysis using the FL1-H channel of a BD 
FACSCalibur Flow Cytometer (BD Biosciences) supported by BD CellQuest Pro 
Software. A minimum of 1 x 104 gated events were acquired per trial. Mean fluorescence 
(specifically: geometric mean fluorescence) was understood to be directly proportional to 
levels of intracellular ROS. In early experiments, a H2O2 control was also analyzed to aid 
in calibrating the flow cytometer for this assay.  
 
Active caspases 3/7-based apoptosis detection assay 
The cell permeable, carboxyfluorescein-labeled fluoromethyl ketone peptide 
inhibitor, fluorochrome inhibitors of caspases (FLICA), covalently binds to a reactive 
cysteine residue that resides on the large subunit of an active caspase heterodimer, 
thereby inhibiting further enzymatic activity. The bound labeled reagent is retained 
within the cell, while any unbound reagent will diffuse out of the cell and is washed 
away. The green fluorescent signal is a direct measure of the amount of active caspase-3 
and caspase-7 present in the cell at the time the reagent was added. Active caspase-3/7 
activity was assessed via flow cytometric analysis of control and treated cells that were 
stained with FLICAI using the CaspaTag Caspase-3/7 In Situ Assay kit (Chemicon 
International, Temecula, CA, USA). Cells were seeded onto sterile flat-bottom 25 cm2 
culture flasks (Corning) and grown overnight to achieve the desired confluence. Cells 
were subjected to iron, SDG or SDG pre-treatment followed by iron treatments in serum- 
and antibiotic-free media. Following the treatment the cells were washed with wash 
buffer and suspended via trypsinization in PBS to achieve 1 x 107 cells / mL. 10 μL of 
freshly prepared FLICA reagent was added to 290 μL of cell suspension, mixed gently 
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and incubated at 37 °C for 1 hour in the absence of light (mixing gently twice during this 
incubation). Following several wash and count steps, samples were immediately analyzed 
via flow cytometry with a BD FACSCalibur Flow Cytometer (BD Biosciences) 
supported by BD CellQuest Pro Software on the FL1-H (FLICA) channel, acquiring a 
minimum of 1 x 104 gated events per trial.  
 
Superoxide dismutase activity assay 
Superoxide dismutases (SODs) catalyze the dismutation of the superoxide radical 
(O2-) into H2O2 and elemental oxygen (O2) which diffuses into the intermembrane space 
or mitochondrial matrix, providing an important defense against the toxicity of 
superoxide radicals [268]. In the Superoxide Dismutase Assay (Trevigen, Helgerman Ct. 
Gaithersburg, MD, USA), ions generated from the conversion of xanthine to uric acid and 
H2O2 by xanthine oxidase, converts nitro-blue tetrazolium chloride (NBT) to NBT-
diformazan, which absorbs light at 550 nm. SOD reduces superoxide ion concentrations, 
thereby lowering the rate of NBT-diformazan formation, which can thus be used to 
measure the SOD activity present in an experimental sample [269]. Cells were seeded 
onto sterile 150 cm2 culture flasks (Corning) and grown overnight to achieve the desired 
confluence. Cells were subjected to iron, SDG or SDG pre-treatment followed by iron 
treatments in serum- and antibiotic-free media. Immediately following challenge, pelleted 
cell samples were lysed and their total protein quantitated via DC Protein Assay (Bio-
Rad), being careful to keep protein samples cold to prevent degradation. Samples were 
assayed as per the kit’s instructions and absorbance read at 550 nm using a PharmaSpec 
UV-1700 Visible Spectrophotometer (Shimadzu, Columbia, MD, USA). The SOD 
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activity was measured by calculating absorbance at 330 seconds subtracted by absorbance 
at 30 seconds, where greater SOD activity would be evidenced by less change in 
absorbance over time. These values were converted to SOD units per volume by 
reference to an SOD inhibition curve, generated as per the kit’s instructions. 
 
RNA isolation 
 RNA isolation was performed using the Aurum Total RNA Mini kit (Bio-Rad) in 
accordance with the manufacturer’s instructions using certified RNase-free barrier tips 
(Ambion, Foster City, CA, USA). Cells were seeded onto sterile 25 cm2 culture flasks 
(Corning) and grown overnight to achieve the desired confluence. Cells were subjected to 
iron, SDG or SDG pre-treatment followed by iron treatments in serum- and antibiotic-
free media. Adherent cells were washed once with PBS and detached via trypsinization. 
Following centrifugation (500 × g for 5 min at 4 °C), cells were washed with PBS and 
lysed using the provided lysis and binding buffer containing components for stabilization 
of RNA and inhibition of RNase activity. Lysates were placed in RNAse-free microfuge 
tubes (Ambion) and RNA was extracted using a silica membrane spin column. Upon 
loading the RNA onto the column, genomic DNA was digested with an RNase-free 
DNase enzyme and, following washes to remove degraded genomic DNA, salts, and 
other cellular components, an elution buffer of low ionic strength was used to collect the 
pure RNA from the column. Aliquots were stored at -80 °C unless being used 
immediately, in which case they were kept on ice and separated into stock and sample 
aliquots, the latter used for RNA quantitation. 
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Automated electrophoretic RNA analysis 
 The concentration and integrity of extracted RNA was assessed using the 
Experion RNA StdSens kit (Bio-Rad) on an Experion Automated Electrophoresis Station 
(Bio-Rad) supported by Experion software for Windows (Bio-Rad), in accordance with 
the manufacturer’s instructions. Briefly, 1 μL aliquots of denatured RNA samples and 
ladder were loaded onto a microfluidic chip comprised of channels that, once primed with 
a gel matrix, allowed for the separation, staining, detection, and data analysis of samples 
by via measurement of the 18 and 28 S rRNA peaks. Only high-quality (i.e. 9+ RNA 
quality index, as per automatic Experion software calculation) RNA samples were used 
for subsequent gene expression analysis.  
 
cDNA synthesis 
 First strand complementary DNA (cDNA) synthesis reactions were performed 
using a RevertAid H Minus First Strand cDNA Synthesis kit (Fermentas, Flamborough, 
ON, Canada) in accordance with the manufacturer’s instructions. This kit features reverse 
transcriptase with a point mutation that completely eliminates RNase H activity and, in 
concert with the kit’s RNase inhibitor, helps prevent RNA degradation during cDNA 
synthesis. Briefly, RNA samples were mixed with oligo(dT)18 primers and the other kit 
components and incubated at 42 °C for 1 hour before terminating the reaction by heating 
at 70 °C for 5 minutes. The resultant products were stored at -20 °C unless being used 
immediately, in which case they were kept on ice. 
 
Quantitative real-time polymerase chain reaction 
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 Quantitative real-time PCR (qPCR) was performed using primers for various 
genes (SABiosciences, Frederick, MD, USA) and SYBR Green RT2 qPCR Master Mix 
(SABiosciences) via iQ5 Multicolor Real-Time PCR Detection System (Bio-Rad) in 
accordance with the manufacturer’s instructions. Briefly, 10 μL of 2x Master Mix was 
pipetted into the wells of a sterile 96-well PCR plate (Bio-Rad). Primer was added to 
nuclease-free ddH2O at a ratio of 1 μL primer to 8 μL ddH2O, and then 9 μL of the mix 
was pipetted into the wells of the PCR plate, followed by 1 μL cDNA template. The PCR 
plate was sealed with optical film (Bio-Rad). Following iQ5 calibration, qPCR analysis 
of triplicate samples was performed using a two-step cycling program involving an initial 
single cycle of 95 °C for 10 min (required to activate the DNA polymerase), followed by 
40 cycles of 95 °C for 15 seconds and 60 °C for 1 minute. Following the qPCR reaction, 
a first derivative dissociation curve was performed as a quality control measure. Briefly, 
the reaction was heated to 95 °C for 1 min, cooled to 65 °C for 2 min, then ramped from 
65 to 95 °C at a rate of 2 °C per minute. The formation of a single peak at temperatures 
greater than 80 °C indicated the presence of a single PCR product in the reaction mixture. 
Gene of interest expression was normalized to the housekeeping gene β2-microglobulin. 
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Table 1 Quantitative real-time PCR primers. These primer sets were used as per 
manufacturer’s instructions, as described above. 
Gene name  UniGene # RefSeq 
Accession # 
Band Size 
(bp) 
Reference 
Position  
Source
Tumour necrosis factor-α Rn.2275 NM_012675 59 1642 SABiosciences
Interleukin-10 Rn.9868 NM_012854 102 34 SABiosciences
Interferon-γ Rn.10795 NM_138880 71 275 SABiosciences
Matrix metalloproteinase 2 Rn.6422 NM_031054 164 2775 SABiosciences
Matrix metalloproteinase 9 Rn.10209 NM_031055 138 2883 SABiosciences
Glutathione reductase  Rn.19721 NM_053906 101 1182 SABiosciences 
Peroxiredoxin 6 Rn.42 NM_053576 118 587 SABiosciences 
Superoxide dismutase 2 Rn.10488 NM_017051 143 553 SABiosciences 
Microtubule-associated 
proteins 1 light chain 3B 
Rn.41412 NM_022867 158 308 SABiosciences 
Β2-microglobulin Rn.1868 NM_012512 128 119 SABiosciences 
 
  
Total protein assay 
 Cell samples for use in immunoblotting were lysed using Nonidet P40 (NP-40) 
(Roche Diagnostics, Germany) buffer containing 150 mM NaCl, 1% NP-40, 50 mM Tris 
(pH 8.0) and protease inhibitors phenylmethylsulfonyl fluoride, leupeptin, aprotinin and 
pepstatin. Inhibitors were added immediately prior to NP-40 buffer application. Upon 
addition of ice-cold lysis buffer to pelleted cell samples, the crude lysate was pipetted up 
and down repeatedly. Lysates were vortexed, incubated on ice for 10 minutes, vortexed 
again and incubated on ice for a further 10 minutes. Lysates were then centrifuged for 12 
minutes at 1 x 104 rpm to remove cellular debris. Supernatant was collected and stored at 
- 80 °C. Protein lysates were quantitated via a detergent-compatible, colourimetric, 
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Lowry-based protein assay. Using the DC Protein Assay (Bio-Rad)’s ‘microplate’ 
method, which requires 5 μL of protein lysate, full-strength and 1/10-strength samples 
were measured alongside a range of bovine serum albumin (BSA; Fisher) standard 
concentrations from 0.2-1.5 mg / mL. Following a 15-minute colour-development period, 
standard and sample absorbance was measured spectrophotometrically at a wavelength of 
750 nm using a PowerWave XS Microplate Spectrophotometer (BioTek). Microsoft 
Excel for Macintosh was used to create a standard curve from the BSA standards, and the 
equation of the line of best fit (minimum accepted R2 = 0.99) was used to calculate the 
sample protein concentrations. Stock sample lysates were kept on ice to minimize 
degradation during the course of the assay. 
 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
 Immediately following quantitation, 2x SDS sample loading buffer containing ß-
mercaptoethanol (Sigma-Aldrich) was added to the sample lysates, which were then 
placed in a 100 °C water bath for 5 minutes (with punctured tube lids to alleviate 
pressure) and then on ice for an additional 5 minutes. Boiled lysates were quick-spun and 
loaded into 10 % sodium dodecyl sulfate-polyacrylamide gels at 50 μg per well (Bio-Rad 
Mini PROTEAN 3 Cell System apparatus was used). 3-5 μL of HiMark™ Pre-stained 
protein standard (Invitrogen) or Precision Plus Kaleidoscope (Bio-Rad) protein standard 
was loaded alongside the sample wells. Empty wells were partially filled with 2x SDS 
loading buffer to ensure even migration across the gel. The electrophoresis apparatus was 
filled with 1x Running buffer (standard 1x Running buffer was prepared from a 10x 
stock). Gels were run at 80 V for 20 minutes or until the sample front cleared the stacking 
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gel, followed by 100 V until the appropriate kDa range had migrated to the centre of the 
resolving gel, as indicated by reference to the protein standard indicator. 
 
Electrophoretic transfer 
Immediately upon completion of sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (to prevent protein band dissociation), gels were removed from the 
electrophoresis assembly, their edges trimmed and orientation marks added (i.e. diagonal 
edge cut at top-left), and then were soaked in 1x Transfer buffer for ~10 minutes for 
equilibration (standard 1x transfer buffer was prepared from a 10x stock). Polyvinylidene 
fluoride transfer membrane (Pierce, Rockford, IL, USA) was soaked in methanol for ~15 
minutes. The transfer cassette was assembled as per the manufacturer’s instructions, filled 
with 1x Transfer buffer, and the transfer was performed at 100 V for 1 hour 30 minutes 
on ice with ddH2O ice blocks. 
 
Protein immunoblot and antibodies 
 Following electrophoretic transfer membranes were stained with Ponceau S 
solution (Bio-Rad) for 5-10 minutes to verify transfer efficiency (i.e. substantial Ponceau 
S staining of the membranes), and Ponceau S stain was removed by successive washes in 
ddH2O. The membranes were then soaked in Tris-buffered saline containing 0.1 % 
Tween-20 detergent (TBST) (Sigma) for 3x 5 minutes (protein side up) to wash and 
equilibrate them before being blocked with 5 % BSA solution for 1hour 30 minutes at 
room temperature or 16 hours at 4 °C. Blocked membranes were incubated with 1:1000 
primary antibody in 5% BSA on a Belly Dancer shaker (Stovall) for 1hour 30 minutes at 
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room temperature or ~14 hours at 4 °C. β-actin, Bax and Bcl 2 antibodies were purchased 
from Santa Cruz Biothechnology, Santa Cruz, CA. Caspase 3, AMPK, FOXO3 and 
p70S6K1 antibodies from Cell Signaling Technology, New England. Membranes were 
then washed in TBST 3x 10 minutes. Following this step, 1:5000 HRP-conjugated goat 
anti-rabbit or anti-mouse IgG secondary antibodies (Pierce) in 5 % BSA solution were 
used to probe the membrane on a shaker for 1 hour 30 minutes at room temperature. 
Following this step, membranes were again washed with TBST 3x 10 minutes. Following 
chemiluminescent imaging, membranes were stripped for re-blotting. 
 
Chemiluminescent imaging and densitometry 
Enhanced chemiluminescence (ECL) utilizes horseradish peroxidase enzyme 
(HRP) attached to the molecule of interest through labeling an immunoglobulin that 
specifically recognizes the molecule. Standard ECL was performed to detect protein-
banding patterns on the immunoblots by virtue of the HRP-conjugated secondary 
antibodies. Chemiluminescent immunoblots were detected via 10-minute High-
Sensitivity Chemiluminescent exposures using a Chemidoc XRS imager (Bio-Rad) 
supported by Quantity One software for Windows (Bio-Rad). Brief Epi-White exposures 
were also collected in order to interpret chemiluminescent banding patterns with the 
membranes’ visible protein ladders. Blots were analyzed via densitometry using the 
Quanity One software, with reference to β-actin control. 
 
Statistics 
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 Data were presented as mean ± standard error of the mean (SEM), and all data 
presented here represents n ≥ 3 independent experiments. Statistical analyses were 
performed using GraphPad Prism software. One-way ANOVA with post hoc Tukey’s test 
were utilized when possible with p < 0.05 considered significant. Asterisks are used 
herein to denote significance according to the following scheme: */# = p < 0.05; **/## = 
p < 0.01; ***/### = p < 0.001. 
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Results 
 
Effect of iron and SDG on cell viability  
 H9c2 cells were subjected to various concentrations of iron treatment (0.1, 1, 10, 
50, 100, 200 and 300 μM iron) for 24 hours at 37 °C, 5 % CO2. Cell viability was 
assessed via the colourimetric MTT assay, wherein MTT reagent was added to cultures at 
t = 20 hours and incubated for the remaining 4 hours before analysis at t = 24 hours. All 
seven iron concentrations induced a significant decrease in cell viability (0.1 μM iron 
decreased 19.10 ± 10.31%, p < 0.001; 1 μM iron decreased 21.51 ± 9.76%, p < 0.001; 10 
μM iron decreased 29.14  ± 15.51%, p < 0.001; 50 μM iron decreased 39.12 ± 9.28%, p < 
0.001; 100 μM iron decreased 39.03 ± 12.04%, p < 0.001; 200 μM iron decreased 70.47 ± 
5.51%, p < 0.001 and 300 μM iron decreased 70.19 ± 4.99%, p < 0.001) when compared 
to control (Figure 5). 50 μM iron treatment was chosen for all further experiments 
because it was the lowest iron concentration that induced appreciable decrease in cell 
viability. To determine if SDG will negatively affect cell viability cells were treated with 
various concentrations of SDG (10, 50, 100 and 500 μM SDG) for 24 hours. Cells were 
pre-treated for 24 hours with all four SDG concentrations in addition to 24 hour treatment 
with 50 μM iron. Only 100 μM SDG caused a small but significant decrease in cell 
viability (13.29 ± 7.38%, p < 0.001) when compared to control (Figure 6). 500 μM SDG 
treatment with and without iron treatment was the only SDG treatment that did not cause 
a significant decrease in cell viability when compared to control but did cause an increase 
in viability when compared to just iron treatment (SDG increased 25.15 ± 34.04%, p < 
0.001; SDG + iron increased 18.87 ± 13.91%, p < 0.01) (Figure 6), so 500 μM SDG 
treatment was chosen for further experiments. 
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Effect of SDG on iron-induced oxidative stress in H9c2 cardiomyocytes 
Iron-induced oxidative stress was investigated in cultured H9c2 cells. Intracellular 
ROS levels were assessed using the CM-H2DCFDA assay and measured via flow 
cytometry. 24-hour treatment with 50 μM iron caused a significant increase (44.52 ± 
4.37%, p < 0.01) in ROS generation (Figure 7) as indicated by increased mean FL1 
fluorescence versus control. These data indicate a pronounced elaboration of ROS 
resulting from iron treatment of the H9c2 cells. Given the observed iron-induced ROS 
elaboration, the potential protective antioxidant effect of SDG was investigated. 24-hour 
pre-treatment with 500 μM SDG abrogated the significant increase in iron-induced ROS 
generation, relegating it to near control levels (Figure 7). This finding indicates that the 
observed iron-induced increase in ROS was attenuated by pre-treatment with SDG. 
 
Effect of SDG on iron-induced inflammatory cytokine expression in H9c2 cardiomyocytes 
 The effect of iron on the expression of tumour necrosis factor (TNF)-α, 
interleukin (IL)-10, and interferon (IFN)-γ was investigated via qPCR. Iron treatment 
caused significant increases in TNF-α (3.23 ± 0.34 fold, p < 0.001) (Figure 8.1), IL-10 
(1.10 ± 0.44 fold, p < 0.05) (Figure 8.2), and IFN-γ (3.39 ± 0.90 fold, p < 0.01) (Figure 
8.3) versus control. These data indicate greatly enhanced expression of key inflammatory 
mediators in response to iron treatment. Pre-treatment with SDG abrogated the significant 
increase in iron-induced TNF- α and IL-10 expression, maintaining it at near-normal, 
control levels (Figure 8.1, 8.2). IFN-γ expression significantly decreased when treated 
with SDG and iron when compared to iron treated cells (1.56 ± 0.69 fold, p < 0.05) 
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(Figure 8.3). These data indicate that SDG can abrogate the iron-induced increased 
expression of inflammatory cytokines. 
 
Effect of SDG on iron-induced matrix metalloproteinase expression in H9c2 
cardiomyocytes 
 Since oxidative stress and inflammation are demonstrably linked to matrix 
degradation and cardiac remodelling, the expression of matrix metalloproteinases 
(MMP)-2 and -9 was investigated via qPCR. Iron treatment caused significant increases 
in MMP-2 (1.83 ± 0.50 fold, p < 0.01) (Figure 9.1) and MMP-9 (1.76 ± 0.19 fold, p < 
0.001) (Figure 9.2) versus control. These data indicate that these endopeptidases were 
activated upon iron treatment, suggesting extracellular matrix changes under these 
conditions. Pre-treatment with SDG abrogated the significant increase in iron-induced 
MMP-2 and -9 expression, maintaining it at near control levels (Figure 9.1, 9.2).  
 
Effect of SDG on iron-induced antioxidant enzyme expression in H9c2 cardiomyocytes 
 To investigate potential cellular antioxidant responses to the observed iron-
induced increase in oxidative stress, the expression of glutathione reductase (GSR), 
peroxiredoxin (Prdx)-6 and superoxide dismutase (SOD)2 was investigated via 
quantitative real-time PCR (qPCR). Iron treatment caused significant increases in GSR 
(1.95 ± 0.68 fold, p < 0.05) (Figure 10.1), Prdx-6 (6.69 ± 0.38 fold, p < 0.001) (Figure 
10.2) and SOD2 (2.66 ± 0.22 fold, p <0.001) (Figure 10.3) versus control. These data 
indicate a robust antioxidant response to the observed iron-induced increase in ROS. Pre-
treatment with SDG abrogated the significant increase in iron-induced GSR expression, 
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maintaining it at control levels (Figure 10.1). Prdx6 expression levels were similar to the 
control when cells were treated with just SDG. When treated with SDG and iron 
combined Prdx6 expression increased significantly (2.45 ± 1.13 fold, p < 0.05) when 
compared to the control but decreased significantly (p < 0.01) when compared to just iron 
treatment (Figure 10.2). SOD2 expression increased when cells were treated with just 
SDG (Figure 10.3) when compared to control (5.75 ± 0.62 fold, p < 0.001) and iron 
treatment (3.09 ± 0.62 fold; p < 0.01). When cells were treated with SDG and iron SOD2 
expression was similar to the control. These findings suggest that there was an iron-
induced increase in antioxidant expression. 
  
Effect of iron and SDG on SOD concentration 
 To further investigate potential cellular antioxidant responses the concentration of 
SOD in iron and SDG treated cells was measured via the Superoxide Dismutase assay. 
Iron and SDG treatment caused a decrease in SOD concentration (54.88 ± 11.83%, p < 
0.05 and 79.61± 5.11%, p < 0.01 respectively) when compared to the control, while 
combined treatment with SDG and iron lead to an increase in SOD concentration when 
compared to the control and iron treated sample (43.79 ± 29.14%, p < 0.001 and 221.69 ± 
17.41%, p < 0.001 respectively) (Figure 11). This finding suggests that iron-induced 
decrease in SOD activity can be abrogated by treatment with SDG.     
 
Effect of SDG on iron-induced H9c2 cardiomyocyte apoptosis 
To investigate the potential cytotoxicity of the observed iron-induced ROS 
elaboration, the activity of apoptotic proteins, caspases 3 and 7, was assessed using the 
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CaspaTag assay and measured via flow cytometry. Iron caused a significant increase 
(40.86 ± 11.56%, p < 0.01) in apoptosis (Figure 12) as indicated by increased mean FL1 
fluorescence versus control. These data indicate that this concentration of iron was 
cytotoxic to the H9c2 cells, suggesting its feasibility as a model of cardiac iron overload. 
Given the observed SDG-mediated prevention of iron-induced ROS elaboration, the 
potential cytoprotective effect of SDG was investigated. Pre-treatment with SDG 
abrogated the significant increase in iron-induced apoptosis, maintaining it at near control 
levels (Figure 12). This finding suggests that iron- induced activation of effector 
caspases can be attenuated by treatment with SDG. 
 
Effect of iron and SDG on Caspase 3and FOXO3 activity and Bax/Bcl2 ratio 
To further investigate the iron-induced apoptosis Caspase 3, Forkhead box O3 
(FOXO3), Bax, and Bcl2 protein expression was assessed via immunoblotting. Caspase 
3, FOXO3 and Bax protein expression was significantly increased after 24 hour iron 
treatment (3.55 ± 1.53 fold, p < 0.01, 0.88 ± 0.20 fold, p < 0.01 and 4.68 ± 1.80 fold, p < 
0.01 respectively) when compared to control (Figure 13.1, 13.2, 13.3). Pre-treatment 
with SDG abrogated the significant increase in iron-induced Caspase 3, FOXO3 and Bax 
protein expression, maintaining it at near control levels (Figure 13.1, 13.2, 13.3). Bcl2 
protein expression did not change significantly after 24 hour iron treatment when 
compared to control (Figure 13.4). Pre-treatment with SDG lead to a significant increase 
in Bcl2 protein expression when compared to control and iron treatment (10.82 ± 4.37 
fold, p < 0.01 and 9.29 ± 4.37 fold, p < 0.05 respectively) (Figure 13.4). These findings 
further suggest SDG was effective in attenuating iron-induced cell death. 
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Effect of SDG on iron-induced MAP1lc3b1 expression in cardiomyocytes 
 Expression of Microtubule-associated proteins 1 light chain 3B (MAP1lc3b1), a 
gene involved in autophagy, was investigated via qPCR. Iron treatment caused significant 
increase in MAP1lc3b1 (1.59 ± 0.30 fold, p < 0.01) (Figure 14). Pre-treatment with SDG 
abrogated the significant increase in iron-induced MAP1lc3b1expression, maintaining it 
at near control levels (Figure 14), suggesting that SDG can abrogate the iron-induced 
increased expression of autophagy gene MAP1lc3b1. 
 
Effect of iron and SDG on p70S6K1 protein expression 
Cardiac hypertrophy in response to oxidative stress has been reported to result 
from an increase in protein content and activation of p70S6 Kinase 1 (p70S6K1). 
p70S6K1 protein expression was assessed via immunoblotting and was significantly 
increased (4.17 ± 2.26 fold, p < 0.05) after 24 hour iron treatment when compared to 
control (Figure 15). Pre-treatment with SDG abrogated the significant increase in iron-
induced p70S6K1 protein expression, maintaining it at near control levels (Figure 15). 
This finding suggests SDG can prevent iron-induced increases in p70S6K1 protein 
expression. 
 
Effect of iron and SDG on AMPK protein expression 
AMP-activated protein kinase (AMPK) reserves cellular energy content and 
serves as a key regulator of cell survival in response to pathological stress. AMPK protein 
expression was assessed via immunoblotting and protein expression and was significantly 
49   
 
decreased after iron treatment (1.30 ± 0.27 fold, p < 0.05) when compared to control 
levels (Figure 16). Pre-treatment with SDG abrogated the significant decrease in iron-
induced AMPK protein expression, maintaining it at near control levels (Figure 16). This 
finding suggests iron overload can lead to a decrease in AMPK and cell survival, and this 
decrease in protein expression can be prevented by SDG. 
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Figure 5 Effect of iron on cell viability. The effect of iron on the viability of H9c2 cells was 
assessed via measurement of mitochondrial dehydrogenase activity (MTT assay). Cells were 
treated in medium containing 0.1, 1, 10, 50, 100, 200 and 300 μM iron. Bars represent mean ± 
SEM of 3 independent experiments. Data is expressed as mean absorbance (*** = p < 0.001 
versus control). 
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Figure 6 Effect of SDG on iron induced decrease of cell viability. The effect of iron and SDG 
on the viability of H9c2 cells was assessed via measurement of mitochondrial dehydrogenase 
activity (MTT assay). Cells were treated in medium containing 50 μM iron and/or 500 μM SDG. 
Bars represent mean ± SEM of 3 independent experiments. Data is expressed as mean absorbance 
(** = p < 0.01 versus control; *** = p < 0.001 versus control; ## = p < 0.01 versus iron; ### = p 
< 0.001 versus iron). 
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Figure 7 Effect of SDG on iron-induced oxidative stress in cardiomyocytes. The effect of iron 
and SDG on intracellular ROS levels in H9c2 cells was assessed via fluorescent detection of 
oxidation-induced esterase activity (CM-H2DCFDA assay), and analyzed via flow cytometry. 
Cells were treated in medium containing 50 μM iron and/or 500 μM SDG. Bars represent mean ± 
SEM of 3 independent experiments. Data is expressed as mean fluorescence arbitrary units (a.u.) 
(* = p < 0.05 versus control; ## = p < 0.01 versus iron) 
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Figure 8.1 Effect of SDG on iron-induced tumour necrosis factor α mRNA expression in 
H9c2 cardiomyocytes. The effect of iron and SDG on TNF-α mRNA expression in H9c2 cells 
was assessed via qPCR. Cells were treated in medium containing 50 μM iron and/or 500 μM 
SDG. Real-time PCR was performed and results were normalized to β2M and normal expression 
standardized to the control. Bars represent mean ± SEM of 3 independent experiments (*** = p < 
0.001 versus control; ### = p < 0.001 versus iron). 
54   
 
 
Figure 8.2 Effect of SDG on iron-induced interleukin 10 mRNA expression in H9c2 
cardiomyocytes. The effect of iron and SDG on IL-10 mRNA expression in H9c2 cells was 
assessed via qPCR. Cells were treated in medium containing 50 μM iron and/or 500 μM SDG. 
Real-time PCR was performed and results were normalized to β2M and normal expression 
standardized to the control.  Bars represent mean ± SEM of 3 independent experiments (* = p < 
0.05 versus control; ### = p < 0.001 versus iron; ## = p < 0.01 versus iron). 
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Figure 8.3 Effect of SDG on iron-induced interferon γ mRNA expression in H9c2 
cardiomyocytes. The effect of iron and SDG on IFN-γ mRNA expression in H9c2 cells was 
assessed via qPCR. Cells were treated in medium containing 50 μM iron and/or 500 μM SDG. 
Real-time PCR was performed and results were normalized to β2M and normal expression 
standardized to the control. Bars represent mean ± SEM of 3 independent experiments (*** = p < 
0.001 versus control; # = p < 0.05 versus iron). 
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 Figure 9.1 Effect of SDG on iron-induced matrix metalloproteinase 2 mRNA expression in 
H9c2 cardiomyocytes. The effect of iron and SDG on MMP-2 mRNA expression in H9c2 cells 
was assessed via qPCR. Cells were treated in medium containing 50 μM iron and/or 500 μM 
SDG. Real-time PCR was performed and results were normalized to β2M and normal expression 
standardized to the control. Bars represent mean ± SEM of 3 independent experiments (** = p < 
0.01 versus control; ### = p < 0.001 versus iron). 
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Figure 9.2 Effect of SDG on iron-induced matrix metalloproteinase 9 mRNA expression in 
H9c2 cardiomyocytes. The effect of iron and SDG on MMP-9 mRNA expression in H9c2 cells 
was assessed via qPCR. Cells were treated in medium containing 50 μM iron and/or 500 μM 
SDG. Real-time PCR was performed and results were normalized to β2M and normal expression 
standardized to the control.  Bars represent mean ± SEM of 3 independent experiments (*** = p < 
0.001 versus control; ### = p < 0.001 versus iron). 
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Figure 10.1 Effect of SDG on iron-induced glutathione reductase mRNA expression in H9c2 
cardiomyocytes. The effect of iron and SDG on GSR mRNA expression in H9c2 cells was 
assessed via qPCR. Cells were treated in medium containing 50 μM iron and/or 500 μM SDG. 
Real-time PCR was performed and results were normalized to β2M and normal expression 
standardized to the control. Bars represent mean ± SEM of 3 independent experiments (* = p < 
0.05 versus control; ## = p < 0.01 versus iron). 
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Figure 10.2 Effect of SDG on iron-induced peroxiredoxin 6 mRNA expression in H9c2 
cardiomyocytes. The effect of iron and SDG on Prdx6 mRNA expression in H9c2 cells was 
assessed via qPCR. Cells were treated in medium containing 50 μM iron and/or 500 μM SDG. 
Real-time PCR was performed and results were normalized to β2M and normal expression 
standardized to the control. Bars represent mean ± SEM of 3 independent experiments (*** = p < 
0.001 versus control; * = p < 0.05 versus control; ### = p < 0.001 versus iron; ## = p < 0.01 
versus iron). 
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Figure 10.3 Effect of SDG on iron-induced superoxide dismutase 2 mRNA expression in 
H9c2 cardiomyocytes. The effect of iron and SDG on SOD2 mRNA expression in H9c2 cells 
was assessed via qPCR. Cells were treated in medium containing 50 μM iron and/or 500 μM 
SDG. Real-time PCR was performed and results were normalized to β2M and normal expression 
standardized to the control.  Bars represent mean ± SEM of 3 independent experiments (*** = p < 
0.001 versus control; ### = p < 0.001 versus control; ## = p < 0.01 versus iron). 
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Figure 11 Effect of iron and SDG on SOD concentration in H9c2 cardiomyocytes. The effect 
of iron and SDG on SOD activity in H9c2 cells was assessed via a colourimetric SOD activity 
assay. Cells were treated in medium containing 50 μM iron and/or 500 μM SDG. Bars represent 
mean ± SEM of 3 independent experiments (** = p < 0.01 versus control; * = p < 0.05 versus 
control; ### = p < 0.001 versus iron). 
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Figure 12 Effect of SDG on iron-induced H9c2 cardiomyocyte apoptosis. The effect of iron 
and SDG on H9c2 cellular apoptosis was assessed via the fluorescent detection of active caspase-
3 and -7 (CaspaTag 3/7 assay), and analyzed via flow cytometry. Cells were treated in medium 
containing 50 μM iron and/or 500 μM SDG. Bars represent mean ± SEM of 3 independent 
experiments. Data is expressed as mean fluorescence arbitrary units (a.u.) (** = p < 0.01 versus 
control; ### = p < 0.001 versus iron; ## = p < 0.01 versus iron). 
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Figure 13.1 Effect of iron and SDG on Caspase 3 protein expression in H9c2 
cardiomyocytes. The effect of iron and SDG on Caspase 3 protein expression in H9c2 cells was 
assessed via immunoblotting, where C = control, I = iron, S = SDG and S+I = SDG + iron. Bars 
represent mean ± SEM of 4 independent experiments (** = p < 0.01 versus control; ### = p < 
0.001 versus iron; ## = p < 0.01 versus iron). 
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Figure 13.2 Effect of iron and SDG on FOXO3 protein expression in H9c2 cardiomyocytes. 
The effect of iron and SDG on FOXO3 protein expression in H9c2 cells was assessed via 
immunoblotting, where C = control, I = iron, S = SDG and S+I = SDG + iron. Bars represent 
mean ± SEM of 3 independent experiments (** = p < 0.01 versus control; ## = p < 0.01 versus 
iron; # = p < 0.05 versus iron). 
65   
 
Control Iron SDG SDG + Iron
0
5
10
15 **
##
###
*
Condition
B
ax
/ β 
A
ct
in
 (a
.u
.)
 
Figure 13.3 Effect of iron and SDG on Bax protein expression in H9c2 cardiomyocytes. The 
effect of iron and SDG on Bax protein expression in H9c2 cells was assessed via immunoblotting, 
where C = control, I = iron, S = SDG and S+I = SDG + iron. Bars represent mean ± SEM of 4 
independent experiments (** = p < 0.01 versus control; * = p < 0.05 versus control; ### = p < 
0.001 versus iron; ## = p < 0.01 versus iron). 
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Figure 13.4 Effect of iron and SDG on Bcl2 protein expression in H9c2 cardiomyocytes. The 
effect of iron and SDG on Bcl2 protein expression in H9c2 cells was assessed via 
immunoblotting, where C = control, I = iron, S = SDG and S+I = SDG + iron. Bars represent 
mean ± SEM of 4 independent experiments (** = p < 0.01 versus control; ## = p < 0.01 versus 
iron; # = p < 0.05 versus iron). 
67   
 
 
Figure 14 Effect of SDG on iron-induced MAPlc3b1 mRNA expression in H9c2 
cardiomyocytes. The effect of iron and SDG on MAP1lc3b mRNA expression in H9c2 cells was 
assessed via qPCR. Cells were treated medium containing 50 μM iron and/or 500 μM SDG. Real-
time PCR was performed and results were normalized to β2M and normal expression 
standardized to the control. Bars represent mean ± SEM of 3 independent experiments (** = p < 
0.01 versus control; ### = p < 0.001 versus iron). 
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Figure 15 Effect of iron and SDG on p70S6 Kinase protein expression in H9c2 
cardiomyocytes. The effect of iron and SDG on p70S6 Kinase protein expression in H9c2 cells 
was assessed via immunoblotting, where C = control, I = iron, S = SDG and S+I = SDG + iron. 
Bars represent mean ± SEM of 3 independent experiments (* = p < 0.05 versus control; ## = p < 
0.01 versus iron; # = p < 0.05 versus iron). 
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Figure 16 Effect of iron and SDG on AMPK protein expression in H9c2 cardiomyocytes. 
The effect of iron and SDG on AMPK protein expression in H9c2 cells was assessed via 
immunoblotting, where C = control, I = iron, S = SDG and S+I = SDG + iron. Bars represent 
mean ± SEM of 3 independent experiments (* = p < 0.05 versus control; # = p < 0.05 versus 
iron). 
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Discussion 
 
  Iron overload cardiomyopathy, resulting from primary or secondary iron overload 
disorders, is responsible for considerable cardiovascular morbidity and mortality [10; 
147; 148; 149; 150]. A recent study suggested that free iron in the plasma enters cardiac 
cells via L-type Ca2+ channels as reduced iron, Fe2+ [1; 10]. Fe2+ can then lead to the 
formation of ROS via the Fenton Reaction by interacting with oxygen species produced 
in the electron transport chain in the mitochondria, interconverting between Fe2+ and Fe3+ 
to generate further ROS [4; 5; 151]. Currently, treatment options are limited; the only 
options for patients are phlebotomy and chelation therapy, both can cause detrimental 
side effects, be expensive, inconvenient and are sometimes ineffective [3; 7; 16]. 
Secoisolariciresinol diglucoside is an antioxidant present in flaxseed and is known to 
decrease the production of inflammatory mediators and the superoxide anion. Previous 
studies have shown that SDG prevents the development of hypercholesterolemic 
atherosclerosis, induces angiogenesis-mediated cardioprotection [140; 145; 146], and 
prevents the development of type 1 and type 2 diabetes [140; 144; 145; 152]. We 
investigated the effects of iron overload on oxidative stress, inflammation and apoptosis 
in H9c2 cells. Furthermore, we also inverstigated if SDG can abrogate the unfavourable 
effects of iron overload. 
Iron overload in H9c2 cells resulted in a decrease in cell viability as measured via 
the MTT assay, a commonly used method of measuring toxicity in vitro. After 24 hours 
all seven iron concentrations induced a significant decrease in cell viability. Based on the 
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results obtained 50 μM iron treatment was chosen for all further experiments because it 
was the lowest iron concentration that induced an appreciable decrease in viability but 
there were still enough viable cells to perform further experiments. Cells were treated 
with different concentrations of SDG for 24 hours to investigate if SDG had any 
detrimental effects on cell viability as well as if there was any protection when combined 
with 50 μM iron. 500 μM SDG treatment in the presence or absence of iron treatment 
was the only SDG concentration that did not cause a significant decrease in cell viability 
when compared to control or each other but did cause an improvement in viability when 
compared to iron treatment alone. These data suggests pre-treatment with 500 μM SDG 
prevents the decrease in oxidative phosphorylation caused by iron treatment leading to 
higher metabolic activity and more viable cells. 
Iron-mediated damage likely involves the role of mitochondrially generated ROS. 
Previous studies using the same cell line found that iron overload causes progressive loss 
of intact mitochondrial DNA (mtDNA), decreased expression of respiratory chain 
subunits encoded by mitochondrial, but not nuclear, DNA, and diminished respiratory 
function. They also reported that iron-mediated cytotoxicity involves ROS generated by 
the mitochondrion itself because cells lacking mtDNA are remarkably tolerant of iron 
overload [153]. In our study ROS production was shown to increase in 50 μM iron 
treated cells as shown with the CM-H2DCFDA assay. The increase in levels of ROS in 
excess iron is likely to be caused by the Fenton reaction, as mentioned earlier. Pre-
treatment with SDG abrogated the significant increase in iron-induced ROS generation, 
relegating it to near control levels. This suggests SDG can work as an antioxidant and 
scavenge ROS produced by increased iron.  
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A significant relationship exists between oxidative stress and inflammation in 
cardiovascular diseases leading to heart failure whereby increased ROS has been shown 
to promote pro-inflammatory mediator expression [38; 51; 154]. Cardiovascular diseases 
are associated with inflammation and cytokine modulation [37; 154], and chronic heart 
failure is often characterized by elevated pro-inflammatory cytokine expression [37; 38; 
154; 155]. For an indicator of inflammation mRNA expression of inflammatory 
mediators, TNF-α, IL-10 and IFNγ, was assessed via qPCR. Previous studies have shown 
that there is an increase in pro-inflammatory TNF-α expression in the failing myocardium 
[155]. Among its many effects, TNF-α is an initiator of the extrinsic apoptosic pathway 
[42]. IL-10 is an anti-inflammatory cytokine known to down-regulate the production of 
TNF-α, and it has similarly been detected in failing myocardium [52; 58; 156]. Under 
iron overload conditions, H9c2 cells feature significantly higher expression of pro and 
anti-inflammatory cytokines. Taken together, these data indicate a strong inflammatory 
response in iron overload. Pre-treatment with SDG abrogated the significant increase in 
iron-induced TNF- α and IL-10 expression, maintaining it at near control levels, while 
IFN-γ expression significantly decreased when treated with SDG and iron when 
compared to iron treated cells. These data suggest SDG is capable of preventing the 
increase in inflammation in iron treated cells. 
Matrix metalloproteinases participate in tissue remodelling in cardiovascular 
diseases associated with enhanced oxidative stress [72]. MMP-2 and MMP-9 are the two 
major remodelling proteins in the heart and are known to play key roles in various cardiac 
disease states [76]. A previous study demonstrated that H9c2 cardiomyoblasts exposed to 
oxidative stress exhibited increased MMP2 activity, leading to cleavage and activation of 
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the apoptotic protein, glycogen synthase kinase-3β [72]. It has also been shown that 
MMP-9 is robustly increased during various stages of congestive heart failure [77]. 
Furthermore, studies have shown that MMP-9 has a major role in ventricular remodelling 
associated with endothelial and myocyte apoptosis [77]. In the present iron overload 
condition, we demonstrated increased mRNA expression of both MMP-2 and -9, which 
corresponded with increased oxidative stress and inflammation. This observation is 
consistent with the significant cardiac damage caused by iron overload, whereby matrix 
remodelling plays a role in cardiovascular pathophysiology. Pre-treatment with SDG 
abrogated the significant increase in iron-induced MMP-2 and -9 expressions, 
maintaining it at near control levels.  
Antioxidants scavenge ROS to achieve cellular redox balance. Previous studies 
have reported the levels of antioxidants, SOD and GSH, to be increased while GPx to be 
decreased in cardiac iron overload [157; 158; 159]. GSR is important for maintaining the 
reduced glutathione levels, and SOD2 catalyzes the dismutation of superoxide anion to 
H2O2 [145]. Prdx6 is involved in redox regulation and decomposes H2O2, hydroperoxide 
and peroxynitrite; and its expression is increased in response to H2O2 [160; 161]. In the 
present study, we too have shown an increase in antioxidant expression in response to 
iron, indicating a robust antioxidant response to the observed iron-induced elaboration of 
ROS. However, although these results indicate significant pro- and antioxidant redox 
changes in response to iron, a net oxidizing effect is likely given that this concentration of 
iron was cytotoxic to the H9c2 cells. This is further supported with pre-treatment with 
SDG plus iron treatment, which was near normal control levels. Interestingly, treatment 
with just SDG caused a significant increase in SOD2 expression when compared to 
74   
 
control and iron treatment, respectively. Antioxidant changes in cardiac iron overload 
was also investigated by measuring the concentration of SOD. Iron treatment caused a 
decrease in SOD concentration, which was abrogated by pre-treatment with SDG. In fact, 
pre-treatment with SDG caused an increase in SOD concentration when compared to 
control and iron. This further suggests that iron- induced cytotoxicity is ROS related, and 
that it can be prevented with SDG treatment. Taken together, these findings support the 
conceptual feasibility of this model of cardiac iron overload in terms of it being an iron-
catalyzed, oxidative stress-driven process and that SDG pre-treatment can abrogate iron 
induced oxidative stress. 
Apoptosis is a regulated program of cell death that can be caused by high levels of 
ROS and is mediated by death receptors in the plasma membrane, the mitochondria, and 
the endoplasmic reticulum. Two independent pathways may lead to cardiomyocyte 
apoptosis; intrinsic and extrinsic apoptosis. Both pathways end with the cleavage and 
activation of executioner caspases 3 and 7 [96; 97]. We showed a significant increase in 
activated caspase 3/7 in iron treated cells. Pre-treatment with SDG abrogated the 
significant increase in iron-induced apoptosis, maintaining it at near control levels. To 
further investigate the iron-induced apoptosis, Caspase 3, FOXO3, Bax, and Bcl2 protein 
expression was assessed via immunoblotting. FOXO3 acts as a transcription factor 
known to play important roles in the regulation of apoptosis, while Bax can open 
mitochondrial channels leading to the release of cytochrome c [96; 97; 107]. Caspase 3, 
FOXO3 and Bax protein expression was significantly increased after 24 hour iron 
treatment when compared to control. Pre-treatment with SDG abrogated the significant 
increase in iron-induced Caspase 3, FOXO3 and Bax protein expression. Bcl2 protein 
75   
 
expression did not change significantly after 24 hour iron treatment when compared to 
control. Pre-treatment with SDG lead to a significant increase in Bcl2 protein expression 
when compared to control and iron treatment. Taken together, these data indicate 
concomitant iron-induced increases in apoptosis and a better understanding into the 
mechanism of action of SDG in preventing apoptosis caused by iron overload. 
Autophagy is the lysosomal degradation of proteins and organelles. In the heart, 
autophagy functions predominantly as a pro-survival pathway during cellular stress by 
removing protein aggregates and damaged organelles. When severely triggered the 
autophagic machinery may lead to cell death [97; 110]. Microtubule-associated proteins 
light chain 3 (MAP1lc3B) is a major constituent of the autophagosome, making it a 
reliable marker for autophagy [162]. mRNA expression of MAP1lc3B, measured via 
qPCR, was significantly increased with iron treatment. Pre-treatment with SDG 
abrogated the significant increase in iron-induced MAP1lc3b1expression, maintaining it 
at near control levels. The precise role of autophagy in cardiac iron overload remains to 
be explored.  
  Cardiac hypertrophy occurs in response to oxidative stress, which involves 
activation of p70S6K1 [130]. p70S6K1 protein expression was assessed via 
immunoblotting and was significantly increased after 24 hour iron treatment when 
compared to control. Pre-treatment with SDG abrogated the significant increase in iron-
induced p70S6K1 protein expression, maintaining it at near-normal, control levels. This 
suggests that iron overload may play a role in cardiac hypertrophy that can be prevented 
by pre-treatment with SDG. AMPK reserves cellular energy content and serves as a key 
regulator of cell survival in response to pathological stress. AMPK protein expression 
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was assessed via immunoblotting and protein expression and was found to be 
significantly decreased after iron treatment when compared to control levels. Pre-
treatment with SDG abrogated the significant decrease in iron-induced AMPK protein 
expression. This suggests SDG can promote cell survival in cardiac iron overload. 
We found that iron treatment of cardiac H9c2 cells caused increased oxidative 
stress, inflammation and cell death. This was observed by measuring increases in ROS, 
inflammatory cytokine expression, expression of antioxidants and remodelling proteins, 
apoptosis, autophagy and hypertrophy markers and decreases in cell survival proteins.  
SDG abrogated the observed increases in cellular damage and promoted cell survival, 
suggesting an impressive, heretofore unknown cardioprotective role for this flaxseed 
antioxidant in cardiac iron overload condition. 
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Conclusion 
 
 Cardiac iron overload directly correlates with cardiac dysfunction and may 
ultimately cause heart failure. Cardiac dysfunction is likely caused by a combination of 
oxidative stress and inflammation, which can lead to cell death. SDG is an antioxidant 
phytochemical present in flax seeds that has been shown to prevent the development of 
hypercholesterolemic atherosclerosis, induce angiogenesis-mediated cardioprotection and 
prevent the development of Type 1 diabetes. Here we investigated the role of SDG on 
markers of oxidative stress, inflammation, cell death and autophagy. The results of these 
in vitro studies demonstrated that H9c2 rat cardiac cell were susceptible to iron overload, 
as evidenced by redox and inflammatory imbalance, increased remodeling and 
antioxidant expression, and increased apoptosis. Pre-treatment with SDG abrogated the 
detrimental effects of iron overload, suggesting a possible role for SDG as a 
cardioprotective agent in iron overload condition 
.     
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